27.08.2010 • News

DSM Appoints New Director for Strategy and Acquisitions

New senior vice president in the corporate strategy & acquisitions department -...
New senior vice president in the corporate strategy & acquisitions department - Karin Dorrepaal

Royal DSM, the global life sciences and materials sciences company headquartered in the Netherlands, today announces the following:

Karin Dorrepaal (1961) will join DSM as senior vice president in the corporate strategy & acquisitions department, as of Sept. 1, reporting to Hein Schreuder.

At the end of 2011 Karin is to succeed Hein Schreuder (1951), at present executive vice president corporate strategy & acquisitions, reporting to Feike Sijbesma, CEO and chairman of the managing board.

Karin, a dutch national, has had several non executive roles since leaving the executive board of Schering in Berlin. Within the Schering board Karin was responsible for the business diagnostic imaging as well as the global supply chain and procurement. The supply chain activities included responsibility for chemical and pharmaceutical production, operations and related systems. Prior to joining Schering Karin was with Booz Allen & Hamilton (now Booz & Co.) for 14 years, where she was a leader of the life science practice. Karin Dorrepaal holds a PhD in Medicine as well as an MBA.

Her very strong external network within the industry will give Karin an excellent starting position to impact the strategic course of DSM.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read